Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04877912 · ClinicalTrials.gov registry record

Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening

A clinical trial, sponsored by University of Chicago.

Terminated
Registry status
166
Enrollment target

NCT04877912: Clinical Trial study, sponsored by University of Chicago.

NCT04877912 is a clinical trial that was terminated before completion, run by University of Chicago. The registered enrollment target is 166 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04877912 was terminated before completion, sponsored by University of Chicago.

TERMINATED
Registry status
166 participants
Enrollment target

Study Summary

The purpose of this study is to test an innovative MRI breast cancer screening method in women with mammographically dense breasts as well as other women with moderately increased cancer risk. MRI, combined with other methods of risk assessment, has potential to significantly improve sensitivity to cancer in dense breasts and detect cancer in all cases at a much earlier stage, with far fewer interval cancers than mammography. Previous tests of MRI sensitivity show that this screening could significantly increase the likelihood of detecting invasive cancers resulting in decreased mortality from breast cancer. Suspicious lesions will be defined by the clinical interpretation of the breast MRI images performed by the attending breast radiologists. Based on the radiologist determination that the MRI findings are suspicious (these findings include masses, non-mass enhancement and foci), suspicious lesions will be assigned a Bi-Rads code specifying whether additional work up or biopsy is necessary. These are Bi-Rads codes 0, 4 and 5. False positive diagnosis should be minimized as all attending physicians reading breast MRI at this institution are fellowship trained in breast imaging.

Primary Outcome

The number of abbreviated scans that successfully determines a cancer, confirmed by biopsy, based on the radiologist determination that the MRI findings are suspicious. Suspicious lesions were assigned a Bi-Rads code specifying whether additional work up or biopsy is necessary. These are Bi-Rads codes 0 (incomplete - need additional imaging evaluation), 4 (suspicious for malignancy - biopsy should be considered) and 5 (highly suggestive of malignancy - appropriate action should be taken).

Interventions

  • DIAGNOSTIC_TEST MRI Abbreviated Scan
  • DIAGNOSTIC_TEST Abbreviated MRI Scan

Trial Details

FieldValue
Enrollment Target 166 participants
Start Date 2017-06-01
Est. Completion 2022-05-31
University of Chicago

796 total trials

Why NCT04877912 stopped before completion

NCT04877912 is an observational study that tracks outcomes without assigning an intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 2 interventions - of which MRI Abbreviated Scan is the first listed.

NCT04877912 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04877912 about?

NCT04877912 is a clinical study titled "Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening". The purpose of this study is to test an innovative MRI breast cancer screening method in women with mammographically dense breasts as well as other women with moderately increased cancer risk. MRI, combined with other methods of risk assessment, has potential to significantly improve sensitivity to ...

What is the current status of trial NCT04877912?

This trial is currently terminated. The enrollment target is 166 participants. The study started on 2017-06-01. Estimated completion is 2022-05-31.

What interventions are being tested in trial NCT04877912?

The interventions under investigation include: MRI Abbreviated Scan (DIAGNOSTIC_TEST), Abbreviated MRI Scan (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04877912?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02747303 · 166 participants · Phase 2

    Frameless Stereotactic Radiosurgery for Intact Brain Metastases

  • NCT03806283 · 166 participants

    Mechanisms of Pregnancy Vascular Adaptations

  • NCT04040452 · 166 participants · Phase 4

    Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery

  • NCT04375813 · 166 participants · Phase 2

    Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04877912, the US trial registry maintained by the National Library of Medicine. NCT04877912 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.